COMP <GO>
AVLN vs RAPP // EV/EBITDA & P/E VALUATION
Avalyn Pharma Inc. (NASDAQ) VS. Rapport Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AVLN 1
— RAPP 1
■ METRIC PARITY
LAST: $25.71 (-0.12%) • MKT CAP: $1.14B
valuation
—
LAST: $24.21 (+7.60%) • MKT CAP: $1.16B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVLN VS. RAPP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AVLN | RAPP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -22.90% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -7.58% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.2 | 37.5 | +6.65 | AVLN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.14B | $1.16B | -$21.8M | RAPP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AVLN REV | RAPP REV | AVLN GROSS % | RAPP GROSS % | AVLN FCF | RAPP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | — | -$88.1M |
| FY 2024 | — | $0 | — | — | — | -$67.2M |
| FY 2023 | — | $0 | — | — | — | -$27.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVLN // BETA —
RAPP // BETA —